US › Healthcare

Redhill Biopharma Ltd (RDHL)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.48-3.81%

Last close · 2026-10-16

Latest quarter · ended 2025-06-30

Revenue

$2.0M

Revenue YoY

+58.6%

Net profit

$-2.1M

EPS

$-2.29

EPS estimate

$0.00

Net margin

-101.3%

Key statistics

Market cap

$4.3M

Forward P/E

1,428.6

P/B

0.78

Book value

$0.84

EPS (TTM)

$0.00

52-week high

$2.14

52-week low

$0.43

50-day MA

$0.59

200-day MA

$0.86

Beta

4.90

Analyst view

with an average price target of $19,000.00.

Shareholding

Institutions

3.48%

Largest institutional holders

Fund	Stake
Yorkville Advisors Global, LP	1.37%
Gagnon Securities LLC	0.99%
Citadel Advisors Llc	0.73%
Rhumbline Advisers	0.15%
Lido Advisors, LLC	0.12%
GAMMA Investing LLC	0.08%
Citigroup Inc	0.05%
Federation des caisses Desjardins du Quebec	0.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Redhill Biopharma Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.